ARTICLE | Clinical News
MOB-015: Phase III started
October 10, 2016 7:00 AM UTC
Moberg began an evaluator-blinded, vehicle-controlled, North American Phase II trial to evaluate once-daily MOB-015 for 48 weeks in about 300 patients. Last year, the companies partnered to develop Mo...